Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 10/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26079064 | 0.82 | CYP17A1 (0.43) | CYP17A1MAPKAPK2PSMB8NAMPTATR | |
| SCHEMBL24723482 | 0.80 | CYP17A1 (0.51) | CYP17A1PSMB8NAMPTMAPK14 | |
| SCHEMBL21885914 | 0.79 | CYP17A1 (0.45) | CYP17A1MAPKAPK2PSMB8NAMPTATR | |
| SCHEMBL16562887 | 0.79 | NAMPT (0.43) | CYP17A1MAPKAPK2PSMB8NAMPTMAPK14 | |
| SCHEMBL21885974 | 0.76 | CA1 (0.43) | CYP17A1MAPKAPK2NAMPTATRMAP4K4 | |
| SCHEMBL13827424 | 0.75 | HDAC8 (0.48) | CYP17A1 | |
| SCHEMBL26079041 | 0.74 | HDAC8 (0.46) | CYP17A1MAPKAPK2PSMB8NAMPTMAPK14 | |
| SCHEMBL25381461 | 0.73 | CYP17A1 (0.52) | CYP17A1MAPKAPK2PSMB8NAMPTMAPK14 | |
| SCHEMBL23498179 | 0.73 | LMNA (0.41) | — | |
| SCHEMBL16352595 | 0.73 | NR3C2 (0.39) | CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310400-A9 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310400-A9 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HDAC1, HDAC6, HDAC3 | CYP17A1 2649/4885MAPKAPK2 1951/4885PSMB8 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.